10 results about "Pneumococcal vaccine" patented technology

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

In one aspect, the disclosure relates to pneumococcal vaccines comprising a semisynthetic saponin adjuvant VSA-1. In one aspect, the disclosed vaccines elicit an immune response in a subject that is measurably higher than the response in an otherwise identical subject who receives a vaccine without the semisynthetic saponin adjuvant. In another aspect, the disclosed vaccines are useful across age groups and immunization can be achieved with fewer injections than for standard pneumococcal vaccines. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to novel compounds and formulations. Additionally, the present invention relates to novel compounds and formulations useful for pneumococcal and pneumococcal conjugate vaccines. More specifically, the present invention relates to compositions comprising a pneumococcal conjugate and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or pharmaceutically acceptable salts thereof, formulated as a stable nanoemulsion (referred to herein as an "SNE adjuvant composition" or "SNE").

The present invention relates to immunogenic compositions and vaccine compositions comprising the antigens AliA or immunogenic fragments thereof and PnrA and immunogenic fragments thereof from Streptococcus pneumoniae and uses thereof in the treatment and / or prevention of infections by S. pneumoniae.

A Yersinia pseudotuberculosis strain (designated as YptbS46) was tailored with an Asd+ plasmid pSMV92 that can synthesize high amounts of the Spn pneumococcal surface protein A (PspA) antigen and monophosphoryl lipid A as an adjuvant. The recombinant strain produced outer membrane vesicles (OMVs) enclosing a high amount of PspA protein (designated as OMV-PspA). A prime-boost intramuscular immunization with 30 pg of OMV- PspA induced both memory adaptive and innate immune responses in co-infected mice, reduced the viral and bacterial burden, and provided complete protection against secondary Spn infection. Also, the OMV-PspA immunization afforded significant cross-protection against the secondary Spn A66.1 infection and long-term protection against the secondary Spn D39 challenge. An OMV vaccine delivering Spn antigens can thus be a new pneumococcal vaccine candidate.

The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains stability as a molecule even around neutral pH range.Specifically, the present invention relates to a protein of the following (a) or (b):(a) a protein comprising the amino acid sequence as set forth in SEQ ID NO: 2 and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein; or(b) a protein being a part of the amino acid sequence as set forth in SEQ ID NO: 2, wherein aspartic acid at position 254 is comprised in the part, and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

A Yersinia pseudotuberculosis strain (designated as YptbS46) was tailored with an Asd+ plasmid pSMV92 that can synthesize high amounts of the Spn pneumococcal surface protein A (PspA) antigen and monophosphoryl lipid A as an adjuvant. The recombinant strain produced outer membrane vesicles (OMVs) enclosing a high amount of PspA protein (designated as OMV-PspA). A prime-boost intramuscular immunization with 30 pg of OMV- PspA induced both memory adaptive and innate immune responses in co-infected mice, reduced the viral and bacterial burden, and provided complete protection against secondary Spn infection. Also, the OMV-PspA immunization afforded significant cross-protection against the secondary Spn A66.1 infection and long-term protection against the secondary Spn D39 challenge. An OMV vaccine delivering Spn antigens can thus be a new pneumococcal vaccine candidate.

To provide additional pneumococcal vaccine compositions that can provide complementary protection against pneumococcal serotypes that are not present in currently available vaccines.SOLUTION: Provided is an immunogenic conjugate comprising Streptococcus pneumoniae (S. pneumoniae) serotype 9N polysaccharide conjugated to a CRM197 carrier protein, in which a) the polysaccharide has a molecular weight of 100 kDa to 500 kDa, b) the conjugate has a molecular weight of 1,000 to 10,000 kDa, and c) a ratio of the polysaccharide to carrier protein is 0.8 to 2.0, the conjugate being capable of inducing an immune response against 9N pneumococcal bacteria in a human patient. Also provided is an immunogenic composition comprising the conjugate and a pharmaceutically acceptable carrier.SELECTED DRAWING: Figure 31A

The present invention relates to novel compounds and formulations. In addition, the present invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the present invention relates to compositions comprising a pneumococcal conjugate and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, which are prepared as stable nanoemulsions (referred to herein as "SNE adjuvant compositions" or "SNE").